Microvascular complications: Pathophysiology and management

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 10, Issue 5, 2010, Pages 505-509

  Vithian, Karunakaran ^a   Hurel, Steven ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; DULOXETINE; ERYTHROMYCIN; GABAPENTIN; LOSARTAN; METOCLOPRAMIDE; OPIATE; PREGABALIN; RAMIPRIL; STATIN;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTENSION RETINOPATHY; KIDNEY DISEASE; LASER COAGULATION; MICROALBUMINURIA; PROTEINURIA; REVIEW; RISK FACTOR; SCREENING; STOMACH PARESIS;

EID: 78650312738     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.10-5-505     Document Type: Review

References (32)

1. Goh K, Tooke J. Abnormalities of the microvasculature. In:Wass J, Shalet S (eds). Oxford textbook of endocrinology and diabetes. Oxford: Oxford University Press, 2002:1749-55.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study. UKPDS Group. Lancet 1998;352:837-53.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20. (Pubitemid 34000785)
5. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 2006;48:519-26. (Pubitemid 44843845)
6. Rassam S, Patel V, Kohner EM. The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Physiol 1995;80:53-68.
7. Klein R, Klein BE,Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less thn 30 years. Arch Ophthalmol 1984;102:520-6. (Pubitemid 14127838)
8. Dahl-Jörgensen K, Brinchmann-Hansen O, Hansen KF et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ (Clin Res Ed) 1985;290:811-5. (Pubitemid 15111977)
9. Chantelau E, Kohner EM.Why some cases of retinopathy worsen when diabetic control improves. BMJ 1997;315:1105-6. (Pubitemid 27470301)
10. Royal College of Ophthalmologists. Guideline for diabetic retinopathy. Executive summary. 2005.
11. Axer-Siegel R, Hod M, Fink-Cohen S et al. Diabetic retinopathy during pregnancy. Ophthalmology 1996;103:1815-9.
12. Klein BE,Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40. (Pubitemid 20024727)
13. National Collaborating Centre for Women's and Children's Health. Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period. London: NCCWCH, 2008.
14. Early photocoagulation for diabetic retinopathy, ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766-85.
15. Williams G, Pickup JC. The handbook of diabetes, 3rd edn. Oxford Blackwell Publishing, 2004.
16. Gnudi L, Gruden G, Viberti GC. Pathogenesis of diabetic nephropathy. In: Pickup JC,Williams G (eds). Textbook of diabetes, 3rd edn. Oxford: Blackwell Publishing, 2003:52.1-22.
17. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33. (Pubitemid 29466226)
18. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995;123:754-62.
19. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study. Lancet 2000;355:253-9.
20. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
22. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
23. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. (Pubitemid 351522739)
24. Bakris GL, Ruilope L, Locatelli F et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-85. (Pubitemid 47462081)
25. Boulton AJ, Vinik AI, Arezzo JC et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-62.
26. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians; 2008.
27. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
28. Sandhu S,Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16. (Pubitemid 44036185)
29. Medina RJ, O'Neill CL, Devine A, Gardiner TA, Stitt AW The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 2008;3:e2584.
30. Kawahara S, Hata Y, Kita T et al. Potent inhibition of cicatricial contraction in proliferative vitreoretinal disease by statins. Diabetes 2008;57:2784-93.
31. Keech AC,Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
32. Bachmann MO, Nelson SJ. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. J Epidemiol Community Health 1998;52:45-52.